

Absence of Global Stress Regulation in *Escherichia coli* Promotes Pathoadaptation and Novel c-di-GMP-dependent Metabolic Capability

1 **Nikola Zlatkov¹, Bernt Eric Uhlin^{1*}**

2 ¹The Laboratory for Molecular Infection Medicine Sweden (MIMS), Department of Molecular
3 Biology, Umeå University, Umeå, Sweden

4 ***Corresponding author: bernt.eric.uhlin@umu.se**

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20


21

22

23


[illegible][illegible]

41 **b**



42

43 **c**



44

45

46

47

48 Fig. S1




Fig. S1: Properties of the *rpoS* allele in IHE3034.

(a) Multiple sequence alignment of the *rpoS* allelic variants of NMEC compared to the *rpoS* allele of MG1655. Highlighted in yellow are the strains in which *rpoS* gene is turned into a pseudogene, the point mutation that introduced the stop codon shown in bold and underlined. Highlighted in blue are the point mutations that are typical for the *rpoS* allele of IHE3034F which expresses inactive RpoS.

56 The strains whose *rpoS* allele share the same point mutations of IHE3034F *rpoS* are highlighted in blue too. Common point mutations
57 for all NMEC strains are highlighted in green.

58 (b) The full membrane of the immunoblot against RpoS present in **Fig.1c**.

59 (c) The full membrane of the immunoblot against H-NS present in **Fig.1c**.

60 (d) The full pictures of the Congo Red plates used for the smooth-rugose assay present in **Fig. 1d**.

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

>ycgG2_K1_IHE3034

ttg-ata-ttt-att-ctg-tta-atc-gcc-tgc-gcc-gct-gcc-ttc-ctg-ctt-gat-agg-tat-ttc-aat-aaa-agg-gca-acg-cct-gaa-gag-atc-ctg-cga-cgg-gct-ata-aat-aat-ggg-gag-atc-gtc-cct-ttt-tac-caa-cct-gtg-gta-aat-ggt-cgg-gaa-ggg-aca-ttg-cgg-gga-gtt-gag-gtg-tta-gcc-cgc-tgg-aaa-caa-cct-cac-ggt-gga-tat-ata-tca-ccc-gcg-gca-ttt-att-cca-ctt-gct-gaa-aaa-tgc-gga-tta-atc-gtt-ccg-ctt-acg-caa-agg-ctg-atg-aat-cag-gtt-gcc-aga-cag-gag-aac-gct-atc-gcg-agt-aaa-ctg-ccg-gaa-ggt-ttt-cat-att-ggg-att-aat-ttt-agg-gcc-tcg-cat-att-att-tcg-ccg-acg-ttt-gtc-gac-gag-tgc-tta-aat-tac-cgt-gac-agt-ttt-acc-cgc-cgc-gat-tta-aac-ctt-gtt-ctg-gaa-gtc-acc-gag-cgt-gag-cca-tta-aat-gtt-gat-gaa-agt-ctg-gtt-cag-cgg-ttg-aac-att-ctg-cat-gaa-aat-ggt-ttt-gtc-atc-gcg-ctg-gat-gat-ttc-ggt-act-ggt-tac-tca-ggg-ctt-tct-tat-ctg-cat-gac-ttg-cat-att-gat-tat-atc-aaa-att-gat-cat-agt-ttc-gtt-ggc-cgc-gtc-aac-gca-gac-cca-gca-tca-acc-cga-att-ctg-gat-tgt-gta-ttg-gat-ctg-gcg-cgt-aaa-ctt-tcg-atc-agt-atc-gtc-gct-gaa-gat-gtc-gaa-acg-aaa-gaa-caa-ttt-gac-tat-ctg-aac-caa-aat-aat-atc-aca-ttt-cag-cag-ggt-tat-tat-ttc-tat-aaa-cct-gtt-aca-tac-atc-gac-ctg-gtc-aag-att-atc-ctt-tct-aaa-ccg-aag-gtg-aag-att-gtg-gtt-gag-tga

YcgG	225	LIFILLIACAAFLLDRYFNKSATPEEILRRAINNGEIVPFYQPVVNGRE	274
YcgG2	1	MIFILLIACAAFLLDRYFNKSATPEEILRRAINNGEIVPFYQPVVNGRE	50
YcgG	275	GTLRGVEVLARKQPHGGYISPAAFIPLAEKGLVPLTQSLMNQVARQM	324
YcgG2	51	GTLRGVEVLARKQPHGGYISPAAFIPLAEKGLVPLTQSLMNQVARQM	100
YcgG	325	NAIASKLPEGFHIGINFASASHIISPTFVDECLNFRDSFTRRDLNLVLEVT	374
YcgG2	101	NAIASKLPEGFHIGINFASASHIISPTFVDECLNFRDSFTRRDLNLVLEVT	150
YcgG	375	EREPLNVDESIVQRLNHLHENGFIADDFGTGYSGLSYLHDLHIDYIKI	424
YcgG2	151	EREPLNVDESIVQRLNHLHENGFIADDFGTGYSGLSYLHDLHIDYIKI	200
YcgG	425	DHSFVGRVNDPESTRILDCVLDLARKLSISIVAEGVETKEQLDYLNQNY	474
YcgG2	201	DHSFVGRVNDPESTRILDCVLDLARKLSISIVAEDVETKEQFDYLNQNI	250
YcgG	475	ITFQQGYFYKPVITYIDLVKIILSKPKVKVVE	507
YcgG2	251	ITFQQGYFYKPVITYIDLVKIILSKPKVKIVVE	283

YcgG2	93	MNQVARQMNAIASKLPEGFHIGINFASASHIISPTFVDECLNFRDSFTRRD	142
YcgG2_ATG	1	MNQVARQMNAIASKLPEGFHIGINFASASHIISPTFVDECLNFRDSFTRRD	50
YcgG2	143	LNLVLEVTREPLNVDESIVQRLNHLHENGFIADDFGTGYSGLSYLHD	192
YcgG2_ATG	51	LNLVLEVTREPLNVDESIVQRLNHLHENGFIADDFGTGYSGLSYLHD	100
YcgG2	193	LHIDYIKIDHSFVGRVNDPESTRILDCVLDLARKLSISIVAEDVETKEQ	242
YcgG2_ATG	101	LHIDYIKIDHSFVGRVNDPESTRILDCVLDLARKLSISIVAEDVETKEQ	150
YcgG2	243	FDYLNQNIITFQQGYFYKPVITYIDLVKIILSKPKVKIVVE	283
YcgG2_ATG	151	FDYLNQNIITFQQGYFYKPVITYIDLVKIILSKPKVKIVVE	191

YcgG	317	MNQVARQMNAIASKLPEGFHIGINFASASHIISPTFVDECLNFRDSFTRRD	366
YcgG2_ATG	1	MNQVARQMNAIASKLPEGFHIGINFASASHIISPTFVDECLNFRDSFTRRD	50
YcgG	367	LNLVLEVTREPLNVDESIVQRLNHLHENGFIADDFGTGYSGLSYLHD	416
YcgG2_ATG	51	LNLVLEVTREPLNVDESIVQRLNHLHENGFIADDFGTGYSGLSYLHD	100
YcgG	417	LHIDYIKIDHSFVGRVNDPESTRILDCVLDLARKLSISIVAEGVETKEQ	466
YcgG2_ATG	101	LHIDYIKIDHSFVGRVNDPESTRILDCVLDLARKLSISIVAEDVETKEQ	150
YcgG	467	LDYLNQNIITFQQGYFYKPVITYIDLVKIILSKPKVKVVE	507
YcgG2_ATG	151	FDYLNQNIITFQQGYFYKPVITYIDLVKIILSKPKVKIVVE	191


Fig. S2.

96 e

>YegG2_K1_IHE3034
MNQVARQMNAIASKLPEGFHIGINFSASHIISPFDCLNYRDSFTRDLNLVLVTREPLNVDES
LVQRLNILEHNGFVIALDFGTGSGLSYLHDLHDYIKDHSFVGRVNADPASTRILDCVLDLARK
LSISIVADVTKEQFDYLNQNNITFQGGYYFYKPVTYIDLVKIILSKPKVKIVVE


97

98 f



99

100 g



101

102

103

104

105 Fig. S2.


106

107 h



108


109 i



110


111 Fig. S2.

112 j



113


114 k



115

116

117 Fig. S2.



119

120 Fig. S2: Analysis of the *ycgG2* gene and its product.

121 (a) DNA sequence of *ycgG2* split into triplets. The rare start TTG codon is shown in green, the first internal ATG codon – in blue and
122 the stop TGA codon – in red.

123 (b) Protein alignment of YcgG and Ycg2 showing great similarity between the amino acid residues in the catalytic EAL domain.

124 (c) Protein alignment between YcgG2 and the protein sequence obtained if the protein is translated from the first internal ATG codon
125 (designated as YcgG2_ATG) showing a 100% match and preservation of the EAL amino acid residues.


126 (d) Protein alignment between YcgG and YcgG2_ATG showing preservation of the EAL amino acid residues.

127 (e) Organization of the EAL domain of YcgG2. (Color legend: yellow – residues involved in the EAL domain organization; green –
128 Mg^{2+} - binding residues; blue – c-di-GMP – binding residues; red – glutatamate as a general base catalyst; pink – residues stabilizing
129 the domain).


130 (f) No effect of c-di-GMP concentrations on YcgG2 translation in *in-vitro* transcription/translation of *ycgG2* under the regulation of T7
131 promoter (the YcgG2 product shown with an arrow; one representative replica shown of three independent experiments).

- (g) No effect of ppGpp and pppGpp alarmones on YcgG2 translation in *in-vitro* transcription/translation of *ycgG2* under the regulation of T7 promoter (the YcgG2 product shown with an arrow; one representative replica shown of three independent experiments).
- (h) The full gel of the radioactively labelled YcgG and YcgG2 present in **Fig. 2b** after exposure of 24 hours. The YcgG band was weak and increase of the contrast was applied on the whole picture and then it was used as a main figure.
- (i) The full gel of the radioactively labelled YcgG and YcgG2 present in **Fig. 2b** after exposure of 5 days.
- (j) The full gel of the radioactively labelled YcgG2 and YcgG2-ATG present in **Fig. 2c** after exposure of 24 hours.
- (k) The full gel of the radioactively labelled YcgG2 produced in different concentrations of c-di-GMP present in **Fig. S2f** after exposure of 5 days.
- (l) The full gel of the radioactively labelled YcgG2 produced in different concentrations of ppGpp and pppGpp present in **Fig. S2g** after exposure of 5 days.

159 a




160
161 b




162
163
164
165
166
167
168
169
170 Fig. S3

171 c



172


173 d



174


175 Fig. S3

176 e



177


178 f



179


180 Fig. S3.

181 g




182

183 h



184

185 Fig. S3.



187

188 Fig. S3: Properties of the IHE3034 strain and its $\Delta ycgG2$ deletion mutant.

189 No growth difference observed when IHE3034 bacteria and their corresponding $\Delta ycgG2$ mutant cells were incubated in Artificial
 190 Urine Medium (AUM) (a) and in LB supplemented with 0.5M NaCl (b), one representative replica of three independent experiments is
 191 shown.

192 (c) The full membrane of the immunoblot against YcgG2 present in **Fig.3a**.

193 (d) The full membrane of the immunoblot against OmpA present in **Fig.3a**.

194 (e) The full membrane of the immunoblot against SfaA present in **Fig. 3b**.

- 195 (f) The full membrane of the immunoblot against OmpA present in **Fig.3b**.
- 196 (g) The full membrane of the immunoblot against SfaA present in **Fig.3c**.
- 197 (h) The full membrane of the immunoblot against OmpA present in **Fig.3c**.
- 198 (i) Pictures of Simmon's plates with cropped labelling present in **Fig.3e** (see Box I) and in **Fig. 3f**.

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215






Fig. S4.

233 **b**



234

235 **c**



236

237

238 Fig. S4.

Fig. S4: The impact of the different components of the AUM on SfaA production of IHE3034 bacteria.

(a) SfaA production by IHE3034 bacteria incubated in LB (lane 2, positive control), 0.1% lactic acid (lane 3), 0.04% iron (III) citrate (lane 4), 0.17M urea (lane 5), 2.5 mM CaCl₂ (lane 6), 0.002 M MnSO₄ (lane 7), 0.002 M KCl (lane 8) and 0.013% ammonium sulfate (lane 9). MG1655 protein extract used as a negative control, OmpA levels served as a loading control.

(b) The full membrane of the immunoblot against SfaA present in **Fig. S4a**.

(c) The full membrane of the immunoblot against OmpA present in **Fig. S4a**.

Fig. S5: Graphical representation of the local alignment of the deleted ExPEC *fec* genetic region against the one of MG1655 genome.

(a) Local alignment of NMEC sequences (shown in red, the sequence of IHE3034 shown in blue) against the genome of MG1655 (detailed below).

(b) Local alignment of the uropathogenic and avian pathogenic *E. coli* sequences (shown in red) against the genome (shown below) of MG1655. The alignment of the sequence of ABU83972 showed presence of the *fec* gene cluster (shown in blue).

(c) The full pictures of the plates from ferric citrate *in-vitro* assay depicted in **Fig. 5d**.

298 **Table S1. Indel mutations in the genome of IHE3034F compared to the one of IHE3034**

IHE3034 Locus/Gene	Position	IHE3034	IHE3034F
ECOK1_0515/phage integrase gene	558439	GTGGGACATATT	G
ECOK1_0536/hypothetical gene	574971	T	TAA
ECOK1_0536/hypothetical gene	574973	TGG	T
ECOK1_0536/hypothetical gene	575051	T	TC
ECOK1_0900/ <i>clpA</i> (pseudogene due to frameshift)	931694	CGTAAAGA	C
Intergenic region	1161181	C	CG
Intergenic region	1161182	C	CCG
ECOK1_2031/ <i>uvrY</i>	2054745	G	GGT
Intergenic region	2714858	CGAGTCTTGAGTCTT	C
ECOK1_3036/hypothetical gene	3107961	C	CGTTACCA
ECOK1_3620/hypothetical gene	3716051	CA	C
ECOK1_4442/ <i>btuB</i> (pseudogene due to frameshift)	4567043	A	AC
ECOK1_4650/ <i>dcuA</i>	4790789	CG	C
ECOK1_4680/ <i>queG</i> (pseudogene due to frameshift)	4817885	C	CA
ECOK1_4834/ <i>hyi</i> (pseudogene due to frameshift)	4976703	C	CA

299

300 **Table S2. SNPs mutations in the genome of IHE3034F compared to the one of IHE3034**

IHE3034 Locus/Gene	Position	IHE3034	IHE3034F
ECOK1_0421/ <i>lon</i>	463548	T	G
Intergenic region	558394	C	A
ECOK1_0515/phage site-specific recombinase gene	558421	A	T
ECOK1_0515/phage site-specific recombinase gene	558424	C	T
ECOK1_0515/phage site-specific recombinase gene	558427	C	T
ECOK1_0515/phage site-specific recombinase gene	558437	C	G
ECOK1_0536/hypothetical gene	574949	T	C
ECOK1_0536/hypothetical gene	574963	C	T
ECOK1_0536/hypothetical gene	574979	T	C
ECOK1_0536/hypothetical gene	574996	T	C
ECOK1_0536/hypothetical gene	575003	G	C
ECOK1_0536/hypothetical gene	575005	A	C
ECOK1_0536/hypothetical gene	575026	T	C
ECOK1_0536/hypothetical gene	575028	T	C
ECOK1_0536/hypothetical gene	575035	T	C
ECOK1_0536/hypothetical gene	575037	G	A
ECOK1_0536/hypothetical gene	575038	G	A
ECOK1_0536/hypothetical gene	575042	T	C
ECOK1_0536/hypothetical gene	575045	G	A
ECOK1_0536/hypothetical gene	575063	C	T
ECOK1_0536/hypothetical gene	575066	G	A

ECOK1_0536/hypothetical gene	575081	G	A
ECOK1_0536/hypothetical gene	575083	C	T
ECOK1_0536/hypothetical gene	575089	A	T
Intergenic region	605737	A	C
ECOK1_0657/ <i>gltJ</i>	697000	G	A
ECOK1_0989/ <i>mukF</i>	1022101	T	C
ECOK1_1066/ <i>putA</i>	1108192	C	A
ECOK1_1107/ <i>iroN</i>	1151518	T	C
ECOK1_1107/ <i>iroN</i>	1151560	T	C
ECOK1_1107/ <i>iroN</i>	1151581	A	T
ECOK1_1107/ <i>iroN</i>	1151665	G	A
ECOK1_1107/ <i>iroN</i>	1151767	C	A
ECOK1_1107/ <i>iroN</i>	1152044	A	G
ECOK1_1107/ <i>iroN</i>	1152514	T	C
ECOK1_1108/ <i>iroE</i>	1154149	T	C
ECOK1_1108/ <i>iroE</i>	1154179	G	A
ECOK1_1108/ <i>iroE</i>	1154433	A	G
ECOK1_1109/ <i>iroD</i>	1154671	T	C
ECOK1_1109/ <i>iroD</i>	1154728	C	T
ECOK1_1109/ <i>iroD</i>	1155093	T	C
ECOK1_1109/ <i>iroD</i>	1155094	G	A
ECOK1_1109/ <i>iroD</i>	1155388	G	A
ECOK1_1109/ <i>iroD</i>	1155758	G	A
ECOK1_1110/ABC transporter gene	1155926	C	A
ECOK1_1110/ABC transporter gene	1155974	T	C
ECOK1_1110/ABC transporter gene	1156187	A	G
Intergenic region	1160966	A	G
Intergenic region	1160977	G	A
Intergenic region	1161036	C	T
Intergenic region	1161165	C	T
Intergenic region	1161189	T	A
Intergenic region	1161197	C	T
ECOK1_1112/hypothetical gene	1161357	C	A
ECOK1_1112/hypothetical gene	1161562	C	A
ECOK1_1112/hypothetical gene	1161573	G	T
ECOK1_1112/hypothetical gene	1161575	G	A
ECOK1_1112/hypothetical gene	1161576	T	C
ECOK1_1301/ <i>sitD</i>	1326729	A	G
ECOK1_1301/ <i>sitD</i>	1326803	C	T
ECOK1_1301/ <i>sitD</i>	1326817	T	C
ECOK1_1301/ <i>sitD</i>	1326872	G	A
ECOK1_1302/ <i>sitC</i>	1328078	A	G
ECOK1_1303/ <i>sitB</i>	1328118	A	T

ECOK1_1303/ <i>sitB</i>	1328313	T	C
ECOK1_1303/ <i>sitB</i>	1328373	G	C
ECOK1_1303/ <i>sitB</i>	1328510	T	C
ECOK1_1303/ <i>sitB</i>	1328547	T	C
ECOK1_1303/ <i>sitB</i>	1328646	A	C
ECOK1_1304/ <i>sitA</i>	1328984	C	A
ECOK1_1304/ <i>sitA</i>	1329032	G	A
ECOK1_1304/ <i>sitA</i>	1329041	T	C
ECOK1_1304/ <i>sitA</i>	1329280	T	C
ECOK1_1304/ <i>sitA</i>	1329341	G	A
ECOK1_1304/ <i>sitA</i>	1329683	C	A
ECOK1_1304/ <i>sitA</i>	1329704	C	T
ECOK1_1553/auxiliary transport protein gene	1564992	G	C
ECOK1_2161/hypothetical gene	2187637	C	T
ECOK1_2162/tRNA-Asn gene	2187821	A	G
ECOK1_3005/hypothetical gene	3083132	A	G
ECOK1_3009/phage N-6-adenine-methyltransferase gene	3085261	C	T
ECOK1_3119/ <i>rpoS</i> , pseudogene	3182422	G	C
ECOK1_3120/ <i>rpoS</i> (5' end of the gene before the stop codon)	3182582	C	A
ECOK1_3464/hypothetical gene	3559184	A	G
ECOK1_3519/ <i>sstT</i>	3620440	G	A
ECOK1_3819/ <i>ompR</i>	3901439	T	A
ECOK1_4122/ <i>uhpA</i>	4229388	C	G

301

302

303

304

305

306

307

308

309

310

311

312

313 **Table S3. Bacterial strains used in this work**

Strain	Description/Relevant characteristics	Reference/Source
<i>Escherichia coli</i> strains		
MC4100	F ⁻ , (<i>argF-lac</i>)UI69, <i>araO</i> 139, <i>rpsL</i> 150, <i>ptsF</i> 25, <i>flbB</i> 5301, <i>rbsR</i> , <i>deoC</i> , <i>relA</i>	¹
RH90	MC4100 <i>rpoS</i> 359::Tn10	²
BW25113	F ⁻ , Δ (<i>araD-araB</i>)567, Δ <i>lacZ</i> 4787(::rrnB-3), λ ⁻ , <i>rph</i> -1, Δ (<i>rhaD-rhaB</i>)568, <i>hsdR</i> 514	^{3,4}
JW0604-1	BW25113 Δ <i>citT</i> 750::kan	⁴
MG1655	<i>E. coli</i> K-12 wild type	⁵
IHE3034	Clinical NMEC isolate, O18:K1:H7	⁶
MAM20	Δ <i>ycgG2</i> :: <i>cat</i> mutant of IHE3034	This work
AES1	Δ <i>sfaX</i> :: <i>aph</i> mutant of IHE3034	⁷
AES153	Δ <i>sfaY</i> mutant of IHE3034	This work
NZ7	AES153/pBR322	This work
NZ11	IHE3034/pBR322	This work
NZ67	IHE3034/pMMkatF	This work
NZ70	AES153/pMMkatF	This work
NZ215	IHE3034 Δ <i>ycgG2</i> /pBR322	This work
NZ216	IHE3034 Δ <i>ycgG2</i> /pMMkatF	This work
NZ217	IHE3034 Δ <i>citT</i> ::kan	This work
NZ218	IHE3034 Δ <i>ycgG2</i> Δ <i>citT</i> ::kan	This work
536	Clinical UTI pyelonephritis isolate, O6:K15:H31	⁸
536 Δ 102	536 (<i>leuX</i> ⁻)	⁹
536-21	536 (PAI I ⁺ , PAI II ⁻ , <i>selC</i> ⁻ , <i>leuX</i> ⁻)	¹⁰

536R3	536 (PAI I, PAI II, <i>selC</i>)	¹¹
NZ225	536-21 Δ <i>rpoS::Tn10</i>	This work
NZ226	536R3 Δ <i>rpoS::Tn10</i>	This work
UTI89	Clinical UTI cystitis isolate, O18:K1:H7	¹²
NZ219	UTI89 Δ <i>rpoS::Tn10</i>	This work
RS218	Clinical NMEC isolate, O18:K1:H7	¹³
DH5 α	<i>ednA1 hsdR17 supE44 thi-1 recA1 gyrA relA1</i> Δ (<i>lacZ4A-argF</i>)	¹⁴
IHE1041	Clinical UTI pyelonephritis isolate; O1:K1:H7	Prof. Timo Korhonen, University of Helsinki, Finland
IHE1049	Clinical UTI pyelonephritis isolate; O1:K1:H7	Prof. Timo Korhonen, University of Helsinki, Finland
IHE1402	Clinical UTI pyelonephritis isolate; O6:K2:H1	Prof. Timo Korhonen, University of Helsinki, Finland
IHE1190	Clinical UTI pyelonephritis isolate; O18:K5:H7	Prof. Timo Korhonen, University of Helsinki, Finland
IHE1268	Clinical UTI pyelonephritis isolate; O18:K5:H7	Prof. Timo Korhonen, University of Helsinki, Finland
<i>Vibrio cholerae</i> strains		
C6706	El Tor, Inaba, Str ^R	¹⁵
C6706 <i>luxO</i> ^c	C6706, LuxO (L104Q) constitutively active	¹⁶
NZ44	C6706 <i>luxO</i> ^c /pBAD18	This work
NZ92	C6706 <i>luxO</i> ^c /pNZK16	This work
NZ93	C6706 <i>luxO</i> ^c /pNZK17	This work

314

315

316

317 **Table S4. Plasmids used in this work**

Plasmid	Description/Relevant characteristics	Reference/Source
pBAD18	Cb ^R , ori ColE1, inducible P _{BAD} promoter	¹⁷
pBR322	Cb ^R , Tc ^R , <i>rep</i> ori (pMB1), cloning vector	¹⁸
pMMkatF	Cb ^R , 4.2-kb subclone of <i>rpo</i> _{SEC} in pAT153	¹⁹
pNZK16	Cb ^R , pBAD18, <i>ycgG</i> from MG1655	This work
pNZK17	Cb ^R , pBAD18, <i>ycgG2</i> from IHE3034	This work
pSIM6	Cb ^R , ori SC101, temperature sensitive, carries the α-red recombinase genes, temperature inducible	²⁰
pKD3	Cm ^R , ori R6Kγ, template for generation of cat fragment flanked with FRT sites.	³
pKO3	Cm ^R , ori M13, <i>sacB</i> , <i>repA</i> ^{ts} , suicide vector	²¹

318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333

Primer:	Sequence (5'→3'):
<i>ycgG2delFw</i>	TTTATTCTGTTAATCGCCTGCGCCGCTGCCTTCCTGCTTGTGTGTAGGCTGGAGCTGCTTC
<i>ycgG2delRv</i>	TGTCTATAATTACACCGCACCATGGCCTTGCTGATCAATTTTCACATATGAATATCCTCCTTAG
1312Fw	AGAGCTCATTCTGCCTACATTGTGCTAAAAAATTAA
<i>ycgG2dwdelRv</i>	CCGGATCCTGCCAGCAACCCATTAGCCGCATACTGGCAGTGAGAAAC
EAL6up	GCGGATCCGGCGGTAATGATATTAC
EALdelendup	CTCTATATTGAGACTCTGCAGCAGGGATAATCCTTTTTTCACAGAC
SfaII-3	CGGTCGACGGATCAGCATCACTAGG
EALdelstartdo	CTGCTGCAGAGTCTCAATATAGAGTGACATTACTCCTCCGG
<i>FwsfaHdw</i>	GTGACTTTTAGCTACAAC TAGAATGCAG
<i>ddsfaxRv</i>	ATGCGGCCGCTGATAATCAATATCATTTAGCAAAAGAAAAAGCAA
<i>ycgGK-12Fw</i>	TGAGCTCCAAGCAAATGCGCAATACAC
<i>ycgGK-12Rv</i>	GGGAAGCTTTCACTCAACCACAACCTTCAC
<i>ycgGK1FW</i>	TGAGCTCTGGGATTTTGATATTTATTCTGTTAATCGCCTGC
<i>ycgGK1RV</i>	GGGAAGCTTTCACTCAACCACAATCTTCACCTTCG
pBAD18FW	ATGCCATAGCATTTTATCC
pBAD18RV	GATTTAATCTGTATCAGG
T7PmRBSycgGK-12Fw	GAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTAACTTTAAGAA GGATATACCAATGCGCAATACACTCATACCCATC
ComplRVycgG	AAGCTTTCACTCAACCACAACCTTCACCTTCGGTTTAGAAAGGATA
T7PmRBSycgG2K1 Fw	GAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTAACTTTAAGAA GGATATACCAATTGATATTTATTCTGTTAATCGCCTGC
<i>upcitTFw</i>	AAGCACTTGATAAAATTTGGAAATATTAATTTTCGGAGA
<i>dwcitTRv</i>	GGGTGTGGAAC TCATACATACACTGAA
3120FW	ATGAGTCAGAATACGCTGAAAGTTCA

<i>rpoSRv</i>	TTATTCGCGGAACAGCGCTTCGATATTCA
---------------	-------------------------------

335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359

360 Supplementary Reference:

361 1 Gowrishankar, J. Identification of osmoreponsive genes in *Escherichia coli*: evidence for
362 participation of potassium and proline transport systems in osmoregulation. *J Bacteriol* **164**,
363 434-445 (1985).

364 2 Marschall, C. *et al.* Molecular analysis of the regulation of *csiD*, a carbon starvation-inducible
365 gene in *Escherichia coli* that is exclusively dependent on sigma s and requires activation by
366 cAMP-CRP. *J Mol Biol* **276**, 339-353, doi:10.1006/jmbi.1997.1533 (1998).

367 3 Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in *Escherichia*
368 *coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* **97**, 6640-6645,
369 doi:10.1073/pnas.120163297 (2000).

370 4 Baba, T. *et al.* Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants:
371 the Keio collection. *Mol Syst Biol* **2**, 2006 0008, doi:10.1038/msb4100050 (2006).

372 5 Guyer, M. S., Reed, R. R., Steitz, J. A. & Low, K. B. Identification of a sex-factor-affinity
373 site in *E. coli* as gamma delta. *Cold Spring Harb Symp Quant Biol* **45 Pt 1**, 135-140 (1981).

374 6 Korhonen, T. K. *et al.* Serotypes, hemolysin production, and receptor recognition of
375 *Escherichia coli* strains associated with neonatal sepsis and meningitis. *Infect Immun* **48**, 486-
376 491 (1985).

377 7 Sjöström, A. E. *et al.* The SfaXII protein from newborn meningitis *E. coli* is involved in
378 regulation of motility and type 1 fimbriae expression. *Microb Pathog* **46**, 243-252,
379 doi:10.1016/j.micpath.2009.01.007 (2009).

380 8 Hacker, J. *et al.* Cloning and characterization of genes involved in production of mannose-
381 resistant, neuraminidase-susceptible (X) fimbriae from a uropathogenic O6:K15:H31
382 *Escherichia coli* strain. *Infect Immun* **47**, 434-440 (1985).

383 9 Ritter, A. *et al.* The Pai-associated *leuX* specific tRNA⁵(Leu) affects type 1 fimbriation in
384 pathogenic *Escherichia coli* by control of FimB recombinase expression. *Mol Microbiol* **25**,
385 871-882 (1997).

386 10 Blum, G. *et al.* Excision of large DNA regions termed pathogenicity islands from tRNA-
387 specific loci in the chromosome of an *Escherichia coli* wild-type pathogen. *Infect Immun* **62**,
388 606-614 (1994).

389 11 Dobrindt, U., Cohen, P. S., Utey, M., Muhldorfer, I. & Hacker, J. The *leuX*-encoded
390 tRNA⁵(Leu) but not the pathogenicity islands I and II influence the survival of the
391 uropathogenic *Escherichia coli* strain 536 in CD-1 mouse bladder mucus in the stationary
392 phase. *FEMS Microbiol Lett* **162**, 135-141 (1998).

393 12 Chen, S. L. *et al.* Identification of genes subject to positive selection in uropathogenic strains
394 of *Escherichia coli*: a comparative genomics approach. *Proc Natl Acad Sci U S A* **103**, 5977-
395 5982, doi:10.1073/pnas.0600938103 (2006).

396 13 Silver, R. P., Aaronson, W., Sutton, A. & Schneerson, R. Comparative analysis of plasmids
397 and some metabolic characteristics of *Escherichia coli* K1 from diseased and healthy
398 individuals. *Infect Immun* **29**, 200-206 (1980).

399 14 Hanahan, D. Studies on transformation of *Escherichia coli* with plasmids. *J Mol Biol* **166**,
400 557-580 (1983).

401 15 Thelin, K. H. & Taylor, R. K. Toxin-coregulated pilus, but not mannose-sensitive
402 hemagglutinin, is required for colonization by *Vibrio cholerae* O1 El Tor biotype and O139
403 strains. *Infect Immun* **64**, 2853-2856 (1996).

404 16 Vance, R. E., Zhu, J. & Mekalanos, J. J. A constitutively active variant of the quorum-sensing
405 regulator LuxO affects protease production and biofilm formation in *Vibrio cholerae*. *Infect*
406 *Immun* **71**, 2571-2576 (2003).

407 17 Guzman, L. M., Belin, D., Carson, M. J. & Beckwith, J. Tight regulation, modulation, and
408 high-level expression by vectors containing the arabinose PBAD promoter. *J Bacteriol* **177**,
409 4121-4130 (1995).

410 18 Bolivar, F. *et al.* Construction and characterization of new cloning vehicles. II. A
411 multipurpose cloning system. *Gene* **2**, 95-113 (1977).

412 19 Mulvey, M. R., Sorby, P. A., Triggs-Raine, B. L. & Loewen, P. C. Cloning and physical
413 characterization of *katE* and *katF* required for catalase HP11 expression in *Escherichia coli*.
414 *Gene* **73**, 337-345 (1988).

415 20 Datta, S., Costantino, N. & Court, D. L. A set of recombineering plasmids for gram-negative
416 bacteria. *Gene* **379**, 109-115, doi:10.1016/j.gene.2006.04.018 (2006).

417 21 Link, A. J., Phillips, D. & Church, G. M. Methods for generating precise deletions and
418 insertions in the genome of wild-type *Escherichia coli*: application to open reading frame
419 characterization. *J Bacteriol* **179**, 6228-6237 (1997).

420